JOP20210117A1 - مشتقات أمينو ترايازولو كوينازولين بها استبدال في الموضع-9 كمضادات مستقبل أدينوزين، تركيبات صيدلانية واستخدامها - Google Patents

مشتقات أمينو ترايازولو كوينازولين بها استبدال في الموضع-9 كمضادات مستقبل أدينوزين، تركيبات صيدلانية واستخدامها

Info

Publication number
JOP20210117A1
JOP20210117A1 JOP/2021/0117A JOP20210117A JOP20210117A1 JO P20210117 A1 JOP20210117 A1 JO P20210117A1 JO P20210117 A JOP20210117 A JO P20210117A JO P20210117 A1 JOP20210117 A1 JO P20210117A1
Authority
JO
Jordan
Prior art keywords
pharmaceutical compositions
substituted amino
receptor antagonists
adenosine receptor
quinazoline derivatives
Prior art date
Application number
JOP/2021/0117A
Other languages
English (en)
Inventor
Ali Amjad
Sather Aaron
J Hoover Andrew
Swaminathan Uma
Hennessy Elisabeth
Liu Ping
Cumming Jared
Pan Jianping
Demong Duane
H Graham Thomas
Faruk Mansoor Umar
W Plummer Christopher
Liu Kun
Deng Qiaolin
A Larsen Matthew
Wang Huijun
Zhang Yonglian
Original Assignee
Merck Sharp & Dohme
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=69005832&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JOP20210117(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Merck Sharp & Dohme filed Critical Merck Sharp & Dohme
Publication of JOP20210117A1 publication Critical patent/JOP20210117A1/ar

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

يتعلق الاختراع الحالي، في تجسيماته المتعددة، بتوفير مركبات أمينو ترايازولو كوينازولين بها استبدال في الموضع-9 بالصيغة البنيوية (I): (I)، وأملاح مقبولة صيدلانية منها، حيث تكون الحلقة A، R1 وR2 كما تم تعريفها هنا، تركيبات صيدلانية تشتمل على واحد أو أكثر من هذه المركبات (بمفردها وفي توليفة مع عامل آخر فعال علاجياً واحد أو أكثر)، وطرق لتحضيرها واستخدامها، بمفردها وفي توليفة مع عوامل علاجية أخرى، كمضادات لمستقبلات A2a و/أو A2b، وفي علاج مجموعة متنوعة من الأمراض، الحالات، أو الاضطرابات والتي تتوسط، جزئياً على الأقل، بمستقبل الأدينوزين A2a و/أو مستقبل الأدينوزين A2b.
JOP/2021/0117A 2018-11-30 2019-11-26 مشتقات أمينو ترايازولو كوينازولين بها استبدال في الموضع-9 كمضادات مستقبل أدينوزين، تركيبات صيدلانية واستخدامها JOP20210117A1 (ar)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862774077P 2018-11-30 2018-11-30
PCT/US2019/063136 WO2020112700A1 (en) 2018-11-30 2019-11-26 9-substituted amino triazolo quinazoline derivatives as adenosine receptor antagonists, pharmaceutical compositions and their use

Publications (1)

Publication Number Publication Date
JOP20210117A1 true JOP20210117A1 (ar) 2023-01-30

Family

ID=69005832

Family Applications (2)

Application Number Title Priority Date Filing Date
JOP/2021/0117A JOP20210117A1 (ar) 2018-11-30 2019-11-26 مشتقات أمينو ترايازولو كوينازولين بها استبدال في الموضع-9 كمضادات مستقبل أدينوزين، تركيبات صيدلانية واستخدامها
JOP/2021/0116A JOP20210116A1 (ar) 2018-11-30 2019-11-26 مشتقات أمينو ترايازولو كوينازولين بها استبدال في الموضع-9 كمضادات مستقبل أدينوزين، تركيبات صيدلانية واستخدامها

Family Applications After (1)

Application Number Title Priority Date Filing Date
JOP/2021/0116A JOP20210116A1 (ar) 2018-11-30 2019-11-26 مشتقات أمينو ترايازولو كوينازولين بها استبدال في الموضع-9 كمضادات مستقبل أدينوزين، تركيبات صيدلانية واستخدامها

Country Status (25)

Country Link
US (2) US11312719B2 (ar)
EP (1) EP3886988A1 (ar)
JP (1) JP7241871B2 (ar)
KR (1) KR102653800B1 (ar)
CN (1) CN113329791A (ar)
AR (1) AR117164A1 (ar)
AU (1) AU2019385905B2 (ar)
BR (1) BR112021010427B1 (ar)
CA (1) CA3120862C (ar)
CL (1) CL2021001406A1 (ar)
CO (1) CO2021006888A2 (ar)
CR (1) CR20210271A (ar)
DO (1) DOP2021000104A (ar)
EA (1) EA202191498A1 (ar)
EC (1) ECSP21036982A (ar)
IL (1) IL283334A (ar)
JO (2) JOP20210117A1 (ar)
MA (1) MA54298A (ar)
MX (1) MX2021006329A (ar)
NI (1) NI202100043A (ar)
PE (1) PE20211768A1 (ar)
PH (1) PH12021551196A1 (ar)
SG (1) SG11202105180PA (ar)
TW (1) TW202039496A (ar)
WO (1) WO2020112700A1 (ar)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL2170959T3 (pl) 2007-06-18 2014-03-31 Merck Sharp & Dohme Przeciwciała przeciwko ludzkiemu receptorowi programowanej śmierci PD-1
US11466017B2 (en) 2011-03-10 2022-10-11 Board Of Regents, The University Of Texas System Heterocyclic inhibitors of PTPN11
WO2017210134A1 (en) 2016-05-31 2017-12-07 Board Of Regents, University Of Texas System Heterocyclic inhibitors of ptpn11
KR102611661B1 (ko) 2018-05-02 2023-12-08 나비레 파르마, 인코퍼레이티드 Ptpn11의 치환된 헤테로사이클릭 억제제
JP2021534124A (ja) 2018-08-10 2021-12-09 ナビール ファーマ，インコーポレイティド 癌治療用ｐｔｐｎ１１（ｓｈｐ２）阻害剤としての６−（４−アミノ−３−メチル−２−オキサ−８−アザスピロ［４．５］デカン−８−イル）−３−（２，３−ジクロロフェニル）−２−メチルピリミジン−４（３ｈ）−オン誘導体及び関連化合物
AU2019388872A1 (en) * 2018-11-30 2021-05-27 Merck Sharp & Dohme Llc 7-, 8-, and 10-substituted amino triazolo quinazoline derivatives as adenosine receptor antagonists, pharmaceutical compositions and their use
WO2023158626A1 (en) * 2022-02-16 2023-08-24 Merck Sharp & Dohme Llc Adenosine receptor antagonists, pharmaceutical compositions and their use thereof
WO2023201267A1 (en) 2022-04-13 2023-10-19 Gilead Sciences, Inc. Combination therapy for treating trop-2 expressing cancers
WO2024118460A1 (en) * 2022-11-29 2024-06-06 Merck Sharp & Dohme Llc Adenosine a2a and a2b receptor antagonists, pharmaceutical compositions and use thereof

Family Cites Families (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3957766A (en) 1970-06-19 1976-05-18 Boehringer Mannheim G.M.B.H. Novel nitrofuran compounds and pharmaceutical compositions
DE2109577A1 (de) 1971-03-01 1972-09-14 Boehringer Mannheim Gmbh Antimikrobiell wirksame Nitrofuran Derivate und Verfahren zur Herstellung derselben
US4713383A (en) 1984-10-01 1987-12-15 Ciba-Geigy Corporation Triazoloquinazoline compounds, and their methods of preparation, pharmaceutical compositions, and uses
GB9524395D0 (en) 1995-11-29 1996-01-31 Nickerson Biocem Ltd Promoters
US6759759B2 (en) 2000-08-29 2004-07-06 Tamagawa Seiki Kabushiki Kaisha Rotary contactless connector and non-rotary contactless connector
AR037243A1 (es) 2001-10-15 2004-11-03 Schering Corp Antagonistas del receptor de adenosina a2a,a5-amino-imidazolo-[4,3-e]-1,2,4-triazolo-[1,5-c]pirimidina, composiciones farmaceuticas y el uso de dichos compuestos para la preparacion de un medicamento
PE20030739A1 (es) 2001-11-30 2003-08-28 Schering Corp Antagonistas del receptor de adenosina a2a
IL161716A0 (en) 2001-11-30 2004-09-27 Schering Corp ADENOSINE A2a RECEPTOR ANTAGONISTS
ES2654064T3 (es) 2002-07-03 2024-03-13 Ono Pharmaceutical Co Composiciones inmunopotenciadoras que comprenden anticuerpos anti-PD-L1
WO2004029056A1 (ja) 2002-09-24 2004-04-08 Kyowa Hakko Kogyo Co., Ltd. [１，２，４]トリアゾロ[１，５−ｃ]ピリミジン誘導体
EP1576014B1 (en) 2002-12-23 2011-06-29 Wyeth LLC Antibodies against pd-1 and uses thereof
EP1591527B1 (en) 2003-01-23 2015-08-26 Ono Pharmaceutical Co., Ltd. Substance specific to human pd-1
EP1615931A1 (en) 2003-04-09 2006-01-18 Biogen Idec MA Inc. Triazolopyrazines and methods of making and using the same
MXPA06004722A (es) 2003-10-28 2006-07-05 Schering Corp Procedimiento para preparar 5-amino-pirazolo-[4,3-e]-1,2,4-triazolo[1,5-c]pirimidinas sustituidas.
ES2342082T3 (es) 2004-04-21 2010-07-01 Schering Corporation Antagonistas de receptores a2a de adenosina de pirazolo(4,3-e)-1,2,4-triazolo(1,5-c)pirimidina.
US7472383B2 (en) 2004-08-13 2008-12-30 Sun Microsystems, Inc. System and method for providing exceptional flow control in protected code through memory layers
CN101119998A (zh) 2004-12-21 2008-02-06 先灵公司 吡唑并[1,5－A]嘧啶腺苷A2a受体拮抗剂
KR101339628B1 (ko) 2005-05-09 2013-12-09 메다렉스, 인코포레이티드 예정 사멸 인자 1(ｐｄ-1)에 대한 인간 모노클로날 항체, 및 항-ｐｄ-1 항체를 단독 사용하거나 기타 면역 요법제와 병용한 암 치료 방법
KR101888321B1 (ko) 2005-07-01 2018-08-13 이. 알. 스퀴부 앤드 선즈, 엘.엘.씨. 예정 사멸 리간드 1 (피디-엘1)에 대한 인간 모노클로날 항체
CN101312978A (zh) 2005-09-19 2008-11-26 先灵公司 作为腺苷A2a受体拮抗剂的2－杂芳基－吡唑并－[4,3－e]－1,2,4－三唑并－[1,5－c]－嘧啶
ATE457988T1 (de) 2006-06-26 2010-03-15 Schering Corp A2a-adenosin-rezeptor-antagonisten
PL2170959T3 (pl) 2007-06-18 2014-03-31 Merck Sharp & Dohme Przeciwciała przeciwko ludzkiemu receptorowi programowanej śmierci PD-1
PE20091101A1 (es) 2007-12-18 2009-07-26 Pharminox Ltd AMIDAS DE ACIDO 3-SUBSTITUIDO-4-OXO-3,4-DIHIDRO-IMIDAZO[5,1-d] [1,2,3,5-TETRACINA-8-CARBOXILICO Y SU EMPLEO
AU2009222040A1 (en) 2008-03-04 2009-09-11 Schering Corporation Amino-quinoxaline and amino-quinoline compounds for use as adenosine A2a receptor antagonists
EP2262837A4 (en) 2008-03-12 2011-04-06 Merck Sharp & Dohme PD-1 BINDING PROTEINS
CA2735006A1 (en) 2008-08-25 2010-03-11 Amplimmune, Inc. Pd-1 antagonists and methods of use thereof
WO2010036959A2 (en) 2008-09-26 2010-04-01 Dana-Farber Cancer Institute Human anti-pd-1, pd-l1, and pd-l2 antibodies and uses therefor
KR20210060670A (ko) 2008-12-09 2021-05-26 제넨테크, 인크. 항-ｐｄ-ｌ１ 항체 및 ｔ 세포 기능을 향상시키기 위한 그의 용도
US8435994B2 (en) 2009-11-16 2013-05-07 Merck Sharp & Dohme Corp. Substituted [1,2,4]triazolo[4,3-alpha]quinoxalines as adenosine A2a receptor antagonists
US20130017199A1 (en) 2009-11-24 2013-01-17 AMPLIMMUNE ,Inc. a corporation Simultaneous inhibition of pd-l1/pd-l2
PE20141693A1 (es) 2011-08-01 2014-11-24 Genentech Inc Metodos para tratar el cancer por el uso de antagonistas de union al eje pd-1e inhibidores de mek
US9495379B2 (en) 2012-10-08 2016-11-15 Veritas Technologies Llc Locality aware, two-level fingerprint caching
WO2014101113A1 (en) 2012-12-28 2014-07-03 Merck Sharp & Dohme Corp. Piperazine-substituted 7-methoxy-[1,2,4]triazolo[1,5-c]quinazolin-5-amine compounds with a2a antagonist properties
WO2014101120A1 (en) 2012-12-28 2014-07-03 Merck Sharp & Dohme Corp. Heterobicyclo-substituted-7-methoxy-[1,2,4]triazolo[1,5-c]quinazolin-5-amine compounds with a2a antagonist properties
WO2015027431A1 (en) * 2013-08-29 2015-03-05 Merck Sharp & Dohme Corp. 2,2-difluorodioxolo a2a receptor antagonists
WO2016081290A1 (en) 2014-11-18 2016-05-26 Merck Sharp & Dohme Corp. Aminopyrazine compounds with a2a antagonist properties
US10085991B2 (en) 2014-12-04 2018-10-02 Merck Sharp & Dohme Corp. Formulation inhibiting effects of low acid environment
EP3253390B1 (en) 2015-02-06 2022-04-13 Merck Sharp & Dohme Corp. Aminoquinazoline compounds as a2a antagonist
EP3307067B1 (en) 2015-06-11 2022-11-02 Merck Sharp & Dohme LLC Aminopyrazine compounds with a2a antagonist properties
US10207002B2 (en) 2015-06-26 2019-02-19 Merck Sharp & Dohme Corp. Sustained release formulation and tablets prepared therefrom
WO2017008205A1 (en) 2015-07-10 2017-01-19 Merck Sharp & Dohme Corp. Substituted aminoquinazoline compounds as a2a antagonist
EP3570844B1 (en) 2017-01-20 2023-09-06 Arcus Biosciences, Inc. Azolopyrimidine for the treatment of cancer-related disorders
EP3723754A4 (en) 2017-12-13 2021-05-19 Merck Sharp & Dohme Corp. IMIDAZO [1,2-C] QUINAZOLIN-5-AMINE COMPOUNDS WITH A2A ANTAGONIST PROPERTIES
MX2020012376A (es) 2018-05-18 2021-03-09 Incyte Corp Derivados de pirimidina fusionados como inhibidores de los receptores de adenosina a2a/a2b.
EP3883576A4 (en) 2018-11-20 2022-06-22 Merck Sharp & Dohme Corp. SUBSTITUTED AMINOTRIAZOLOPYRIMIDINES AND AMINO-TRIAZOLOPYRAZINE ADENOSINE RECEPTOR ANTAGONISTS, PHARMACEUTICAL COMPOSITIONS AND THEIR USE
AU2019383948A1 (en) 2018-11-20 2021-05-20 Merck Sharp & Dohme Llc Substituted amino triazolopyrimidine and amino triazolopyrazine adenosine receptor antagonists, pharmaceutical compositions and their use
AU2019388872A1 (en) 2018-11-30 2021-05-27 Merck Sharp & Dohme Llc 7-, 8-, and 10-substituted amino triazolo quinazoline derivatives as adenosine receptor antagonists, pharmaceutical compositions and their use

Also Published As

Publication number Publication date
WO2020112700A1 (en) 2020-06-04
MA54298A (fr) 2022-03-09
BR112021010427B1 (pt) 2022-09-27
US11312719B2 (en) 2022-04-26
BR112021010427A2 (pt) 2021-08-17
AR117164A1 (es) 2021-07-14
IL283334A (en) 2021-07-29
EP3886988A1 (en) 2021-10-06
MX2021006329A (es) 2021-08-11
KR20210096184A (ko) 2021-08-04
DOP2021000104A (es) 2021-07-30
TW202039496A (zh) 2020-11-01
NI202100043A (es) 2021-08-13
KR102653800B1 (ko) 2024-04-01
PH12021551196A1 (en) 2021-11-29
CR20210271A (es) 2021-07-14
JOP20210116A1 (ar) 2023-01-30
US20210107904A1 (en) 2021-04-15
EA202191498A1 (ru) 2021-08-20
CL2021001406A1 (es) 2021-11-12
CA3120862C (en) 2024-05-07
PE20211768A1 (es) 2021-09-07
US20220220117A1 (en) 2022-07-14
JP7241871B2 (ja) 2023-03-17
CN113329791A (zh) 2021-08-31
AU2019385905A1 (en) 2021-06-03
CO2021006888A2 (es) 2021-06-10
SG11202105180PA (en) 2021-06-29
CA3120862A1 (en) 2020-06-04
JP2022511441A (ja) 2022-01-31
AU2019385905B2 (en) 2023-01-12
ECSP21036982A (es) 2021-06-30

Similar Documents

Publication Publication Date Title
PH12021551196A1 (en) 9-substituted amino triazolo quinazoline derivatives as adenosine receptor antagonists, pharmaceutical compositions and their use
PH12020551870A1 (en) Tetracyclic heteroaryl compounds
BR112017007662A8 (pt) Composto, composição farmacêutica e uso de um composto
EP4306523A3 (en) Imidazoquinoline compounds and uses thereof
CL2019003650A1 (es) Imidazopirimidinas diazabicíclicas sustituidas y su uso para el tratamiento de trastornos respiratorios.
MX2018003186A (es) Derivados de 8-[6-[3-(amino)propoxi]-3-piridil]1-isopropilimidazo[ 4,5-c]quinolin-2-ona como moduladores selectivos de la cinasa de la ataxia telangiectasia mutada (atm) para el tratamiento del cancer.
GEP20156417B (en) Pyrrolo [2,3-d] pyrimidine derivatives as inhibitors of tropomyosin-related kinases
MX2021006012A (es) Derivados de amino triazolo quinazolina 7-, 8-, y 10-sustituidos como antagonistas de receptor de adenosina, composiciones farmaceuticas y su uso.
MX2017012411A (es) Co-cristales de un inhibidor de tirosina cinasa de bruton.
MX2021005839A (es) Antagonistas del receptor de adenosina aminotriazolopirimidina y aminotriazolopirazina sustituidos, composiciones farmaceuticas y su uso.
BR112018005589A2 (pt) “composto, composição farmaceuticamente aceitável, e, uso de um composto”
NZ736055A (en) Imidazopyrazines and pyrazolopyrimidines and their use as ampa receptor modulators
AR074240A1 (es) Compuesto 3-(4-cloro-2-fluorobencil )-2-metil-n-(5- metil-1h- pirazol-3-il)-8- (morfolinometil)imidazo (1,2-b)piridazin -6-amina o una sal farmaceuticamente aceptable del mismo, su uso para preparar un medicamento util para el tratamiento de trastornos mieloproliferantes cronicos y condiciones asoci
PH12020500543A1 (en) Nonracemic mixtures and uses thereof
AR107751A1 (es) Composiciones de forma de dosificación que comprenden un inhibidor de tirosina cinasa de bruton
MX2021009117A (es) Pirazolopiridinas y triazolopiridinas como inhibidores receptores de adenosina a2a / a2b.
MX2022006086A (es) Derivados de piridopirimidinona como antagonistas de ahr.
MY201535A (en) Therapeutic compounds
AU2020278236A8 (en) Methods of treating Sjögren's Syndrome using a Bruton's tyrosine kinase inhibitor
MX2021004883A (es) Metodos y composiciones para tratar apnea del sue?o.
MX2022004121A (es) Derivados de homopiperazinil y homopiperidinil quinazolin-4(3h)-ona que tienen actividad multimodal contra el dolor.
MX2021003901A (es) Derivados de 5-azaindazol como antagonistas del receptor de adenosina.
MX2021004885A (es) Derivados de piperazinil y piperidinil-quinazolin-4(3h)-ona que tienen actividad contra el dolor.
MX2018013969A (es) Combinacion de antagonistas del receptor 5-ht6 puro con un antagonista del receptor nmda.
PH12017501736A1 (en) Indole derivatives